$0.84
9.97% yesterday
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US44148G1058
Symbol
HOTH
Sector
Industry

Hoth Therapeutics, Inc. Stock price

$0.84
-0.40 32.27% 1M
+0.01 1.68% 6M
+0.09 12.27% YTD
-0.59 41.27% 1Y
-16.97 95.28% 3Y
-80.41 98.97% 5Y
-212.41 99.61% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.09 9.97%
ISIN
US44148G1058
Symbol
HOTH
Sector
Industry

Key metrics

Market capitalization $11.06m
Enterprise Value $4.05m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.98
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-8.22m
Free Cash Flow (TTM) Free Cash Flow $-6.98m
Cash position $7.04m
EPS (TTM) EPS $-1.34
P/E forward negative
Short interest 2.16%
Show more

Is Hoth Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Hoth Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Hoth Therapeutics, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Hoth Therapeutics, Inc. forecast:

Buy
100%

Financial data from Hoth Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.97 4.97
18% 18%
-
- Research and Development Expense 3.25 3.25
7% 7%
-
-8.22 -8.22
7% 7%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -8.22 -8.22
7% 7%
-
Net Profit -8.19 -8.19
4% 4%
-

In millions USD.

Don't miss a Thing! We will send you all news about Hoth Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hoth Therapeutics, Inc. Stock News

Neutral
PRNewsWire
3 days ago
NEW YORK , April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St. Louis to advance Alzheimer's disease research through a novel therapeutic strategy. The partnership centers on a recently submitted NIH grant proposal focused on studyin...
Neutral
PRNewsWire
3 days ago
Results underscore the dual-action profile of HT-ALZ—impacting both pathology and symptomology. NEW YORK , April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced groundbreaking preclinical data supporting the therapeutic potential of its lead Alzheimer's candidate, HT-...
Neutral
PRNewsWire
4 days ago
NEW YORK , March 31, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that it has received an official Filing Receipt from the United States Patent and Trademark Office (USPTO) for a new patent application related to the proprietary formulation of HT-001, the Company's lead clinical asset. This newly filed a...
More Hoth Therapeutics, Inc. News

Company Profile

Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.

Head office United States
CEO Robbie Knie
Employees 6
Founded 2017
Website www.hoththerapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today